| Literature DB >> 11480129 |
Abstract
Type 2 diabetes is increasingly common and can be difficult to control. By directly targeting insulin resistance, the thiazolidinediones offer a new mode of treatment. Here, the pharmacology, clinical trial evidence, side-effects and current clinical uses of pioglitazone are reviewed.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11480129 DOI： 10.12968/hosp.2001.62.7.1611
Source DB: PubMed Journal: Hosp Med ISSN： 1462-3935